US20140194356A1 - Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein - Google Patents

Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein Download PDF

Info

Publication number
US20140194356A1
US20140194356A1 US14/234,652 US201214234652A US2014194356A1 US 20140194356 A1 US20140194356 A1 US 20140194356A1 US 201214234652 A US201214234652 A US 201214234652A US 2014194356 A1 US2014194356 A1 US 2014194356A1
Authority
US
United States
Prior art keywords
formulation according
formulation
neutral salt
biopharmaceutical protein
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/234,652
Inventor
Bernt Pragl
Sabine Fuertinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to US14/234,652 priority Critical patent/US20140194356A1/en
Assigned to SANDOZ AG reassignment SANDOZ AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUERTINGER, SABINE, Pragl, Bernt
Publication of US20140194356A1 publication Critical patent/US20140194356A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Definitions

  • biopharmaceutical drugs have entered the market, particularly protein drugs, both isolated from biological resources and/or produced with recombinant means.
  • biopharmaceuticals as therapeutics requires the preservation of their biological activity in all steps of development including storage and delivery.
  • proteins pose additional challenges in preserving their activity because they are much larger, contain relatively labile groups, possess fragile three-dimensional structures, and can furthermore be subject of metabolic processes, e.g. by microorganismic contaminations.
  • Degradation may occur in different ways, including aggregation of molecules, denaturation of tertiary structure and deamidation of amino acid residues, e.g. asparagine and glutamine with their amide-containing side chains. Generally, all these processes of degradation are accelerated under suboptimal storage conditions, e.g., raised temperature, exposure to light and/or high relative humidity.
  • Aggregation can take place in form of visible aggregates and sub visible aggregates. Once formed, however, the latter can act as aggregation seeds for the formation of larger (then visible) aggregations.
  • biopharmaceutical drugs are often produced to stock, and are thus subject to relatively long periods of storage times and/or have to undergo long transportation routes before they reach the point of care. This situation is even worsened by the fact that in many cases it cannot be guaranteed that the cooling chain remains unbroken during storage and/or transport.
  • biopharmaceutics reach the point of care in a state of advanced degradation, and can thus need to be discarded, which involves substantial financial losses, e.g., for the healthcare sponsoring institutions, due to the relatively high market prices for biopharmaceutics, and may, in the worst case, isolate a patient from an essential treatment.
  • a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ⁇ 0.7 and ⁇ 5.
  • biopharmaceutical protein relates to physiologically active proteins both isolated from biological resources and/or produced with recombinant means.
  • concentration refers to the weight of a given substance per volume, i.e., to weight concentration.
  • concentration of a biopharmaceutic is provided in a concentration of mg ml ⁇ 1.
  • the weight of the biopharmaceutical protein refers to weight of the protein alone, i.e, to the one or more amino acid chain which constitute the protein, plus, if applicable, the one or more glycosylation patterns.
  • the weight does not include said modifications, which can add substantial additional weight.
  • concentration ratio refers to the dimensionless ratio of the concentrations of at least two substances.
  • the biopharmaceutic is provided in a concentration of 10 mg ml ⁇ 1 and the neutral salt is provided in a concentration of 7.07 mg ml ⁇ 1
  • the inventors have for the first time shown in an aqueous formulation comprising a biopharmaceutical aggregations, particularly sub-visible aggregations can be reduced in case said particular concentration ratio between the biopharmaceutic and the neutral salt is provided.
  • said concentration ratio is 0.7; 0.8; 0.9; 1.0; 1.1; 1,.2; 1.3; 1.4; 1.5; 1.6; 1.7; 1,8; 1.9; 2.0; 2.1; 2.2; 2.3; 2.4; 2.5; 2.6; 2.7; 2.8; 2.9; 3.0; 3.1; 3.32; 3.3; 3.4; 3.5; 3.6; 3.7; 3,8; 3,9; 4; 4.1; 4.2; 4.3; 4.4; 4.5; 4.6; 4.7; 4.8 4.9; or 5.0.
  • the biopharmaceutical protein has between ⁇ 150 and ⁇ 220 amino acid residues and/or a molecular weight between ⁇ 15 and ⁇ 26 kDaltons.
  • the protein has 150; 151; 152; 153; 154; 155; 156; 157; 158; 159; 160; 1641; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 177; 178; 179; 180; 181; 182; 183; 184; 185; 186; 187; 188; 189; 190; 191; 192; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 209; 210; 211; 212; 213; 214; 215; 216; 217; 218; 219 or 220 amino acid residues; and/or a molecular weight of 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25 or 26 k
  • the biopharmaceutical protein is human growth hormone (hGH).
  • Human Growth Hormone hGH is a protein-based peptide hormone which stimulates growth, cell reproduction and regeneration in humans and other animals.
  • hGH is a single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
  • hGH is primarily used to treat children's growth disorders and adult growth hormone deficiency.
  • growth hormone was extracted from human pituitary glands (Cadaver growth hormone, also referred to as NPA growth hormone).
  • hGH is primarily produced with recombinant DNA technology (rhGH, also referred to as somatropin).
  • rhGH has, typically, 191 amino acid residues.
  • the amino acid sequence is available in the UniProt Database under accession No. P01241.
  • met-GH methionyl-growth hormone
  • methionyl-growth hormone has the same amino acid sequence as hGH, with an extra N-terminal methionine.
  • human growth hormone encompasses all the above mentioned variants.
  • the formulation further comprises at least one agent selected from the group consisting of
  • said buffer is selected from the group consisting of:
  • said non-ionic surfactant is selected from the group consisting of:
  • tonifier relates to an osmotically active substance which can be used to affect the osmolarity of a pharmaceutical formulation.
  • said tonifier is selected from the group consisting of:
  • said preservative is selected from the group consisting of:
  • Suitable concentrations for the buffers, non-ionic surfactants, tonifiers, and/or preservatives are for example shown in Table 2.
  • human growth hormone is present in a concentration ranging between ⁇ 3 and ⁇ 20 mg ml ⁇ 1 .
  • hGH is present in a concentration of 3; 3.33; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19 or 20 mg ml ⁇ 1 .
  • Particularly preferred concentrations for hGH are for example shown in Table 2.
  • said neutral salt is selected from the group consisting of:
  • said neutral salt is present in a concentration ranging between ⁇ 2 and ⁇ 100 mg ml ⁇ 1 .
  • said neutral salt is present in a concentration of 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92;
  • concentrations for the neutral salt are for example shown in Table 2.
  • the pH of said formulation is in a range between ⁇ 5,8 and ⁇ 6.2.
  • said pH is 5,8; 5,9; 6; 6,1 or 6,2.
  • Particularly preferred pH values are for example shown in Table 2.
  • the formulation according to the invention has an optimized stability. Said optimized stability results, e.g., in reduced formation of visible and subvisible aggregates, reduced formation of precipitates, reduced tendency to develop turbidity, particularly after long storage or storage under suboptimal conditions.
  • This feature is particularly beneficial under conditions where it cannot be guaranteed that the cooling chain remains unbroken, as its can for example be the case in emerging markets and/or developing countries.
  • aggregates can for example be analyzed with light obscuration Particle Counting, Size exclusion HPLC (SE-HPLC)and/or Dynamic light scattering (DLS).
  • SE-HPLC Size exclusion HPLC
  • DLS Dynamic light scattering
  • Light obscuration Particle Counting is a method that helps to detect and count particles.
  • the nature of particle counting is based upon either light scattering or light obscuration.
  • a high energy light source is used to illuminate the particle as it passes through the detection chamber.
  • the particle passes through the light source (typically a laser) and if light scattering is used, then the redirected light is detected by a photo detector, while, if light obscuration is used, the loss of light is detected. The amplitude of the light scattered or light blocked.
  • SE-HPLC Size exclusion HPLC
  • Dynamic light scattering is a technique in physics, which can be used to determine the size distribution profile of small particles in suspension or polymers in solution. It can also be used to probe the behavior of complex fluids such as concentrated polymer solutions.
  • a method of increasing the stability of a pharmaceutically acceptable aqueous formulation comprising a biopharmaceutical protein comprises providing the biopharmaceutical protein and the neutral salt in a final concentration ratio in the range of ⁇ 0.7 and ⁇ 5.
  • the biopharmaceutical protein is human growth hormone (hGH).
  • a primary packaging comprising the formulation according to the invention.
  • Said primary packaging is preferably a vial, a pre-filled syringe, a carpule, a bottle, or a cartridge.
  • Table 3 shows other aqueous formulations from the prior art comprising human growth hormone, but without a neutral salt.
  • FIG. 1 Particle distribution of samples stored at 5° C. in the first tonifier screening experiment (example 1, “intended storage condition”), as determined with light obscuration Particle Counting.
  • sample 1 “intended storage condition”
  • sub-visible particle levels were high at the initial time point and shows elevated levels for formulations containing no tonifier, Glycine, Mannitol and Sorbitol. NaCl containing formulations showed the lowest sub-visible particle levels.
  • FIG. 2 Particle distribution of samples stored at 25° C. in the first tonifier screening experiment (example 1, “accelerated storage condition”), as determined with light obscuration Particle Counting.
  • sample 1 “accelerated storage condition”
  • sub-visible particle levels were high at the initial time point but stayed at elevated levels for formulations containing no tonifier, Glycine and Sorbitol. NaCl containing formulations showed the lowest sub-visible particle levels.
  • FIG. 3 Particle distribution of samples stored at 40° C. in the first tonifier screening experiment (example 1, “stressed storage conditions”), as determined with light obscuration Particle Counting.
  • sample 1 stressed storage conditions
  • sub-visible particle levels were highest at the initial time point. All formulations stored for 1 week and 2 weeks at 40° C. showed a significant decrease in sub-visible particle levels.
  • FIG. 4 Particle distribution of samples stored at 5° C. in the second tonifier screening experiment (example 3, “intended storage condition”), as determined with light obscuration Particle Counting.
  • sample 3 “intended storage condition”
  • sub-visible particles progressively increase for formulations containing no tonifier and Glycine and pronounced for formulations containing Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels.
  • FIG. 5 Particle distribution of samples stored at 25° C. in the second tonifier screening experiment (example 3, “accelerated storage condition”), as determined with light obscuration Particle Counting.
  • sample 3 “accelerated storage condition”
  • sub-visible particles stayed at elevated levels for formulations containing no tonifier, Glycine, Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels.
  • FIG. 6 Particle distribution of samples stored at 40° C. in the second tonifier screening experiment (example 3, “stressed storage condition”), as determined with light obscuration Particle Counting.
  • sample 3 stressed storage condition
  • sub-visible particle levels were highest at the end of storage after 2 weeks at 40° C.
  • Sub-visible particles were at elevated levels for formulations containing no tonifier, Glycine, Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels.
  • FIG. 7 Particle distribution of samples stored at 5° C. in the optimization of neutral salt concentration experiment (example 2, “intended storage condition”), as determined with light obscuration Particle Counting. Sub-visible particle levels were elevated for all batches except for formulations containing 3.5 mg/ml, 7.07 mg/ml and 14 mg/ml NaCl during storage at 5° C. This finding is further backed by DLS data (data not shown).
  • FIG. 8 Particle distribution of samples stored at 25° C. in the optimization of neutral salt concentration experiment (example 2, “accelerated condition”), as determined with light obscuration Particle Counting. Sub-visible particle levels were elevated for all batches except for formulations containing 3.5 mg/ml, 7.07 mg/ml and 14 mg/ml NaCl during storage at 25° C. This finding is further backed by DLS data (data not shown).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is related to a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5.

Description

  • In the recent years, biopharmaceutical drugs have entered the market, particularly protein drugs, both isolated from biological resources and/or produced with recombinant means.
  • The successful use of such biopharmaceuticals as therapeutics requires the preservation of their biological activity in all steps of development including storage and delivery. Compared to conventional small molcecular drugs, proteins pose additional challenges in preserving their activity because they are much larger, contain relatively labile groups, possess fragile three-dimensional structures, and can furthermore be subject of metabolic processes, e.g. by microorganismic contaminations.
  • Degradation may occur in different ways, including aggregation of molecules, denaturation of tertiary structure and deamidation of amino acid residues, e.g. asparagine and glutamine with their amide-containing side chains. Generally, all these processes of degradation are accelerated under suboptimal storage conditions, e.g., raised temperature, exposure to light and/or high relative humidity.
  • Aggregation can take place in form of visible aggregates and sub visible aggregates. Once formed, however, the latter can act as aggregation seeds for the formation of larger (then visible) aggregations.
  • These problems are even aggravated in case a biopharmaceutic is provided in aqueous formulation. Such type of ready-to-use formulation is however commonplace because of ease and safety of administration, for example for monoclonal antibodies as well as for smaller biopharmaceutics such as insulin, erythropoietin, or human Growth Hormone.
  • Due to the fact that the production of biopharmaceutics is a highly complex matter, production facilities are concentrated in particular clusters where the respective expertise exists. These facilities are not as evenly distributed, geographically, as for example facilities for the production of small molecular drugs. Further, because manufacturing capacities are in short supply, the production of a given drug takes often place in a relatively large batch, and then another drug steps in.
  • For these reasons, biopharmaceutical drugs are often produced to stock, and are thus subject to relatively long periods of storage times and/or have to undergo long transportation routes before they reach the point of care. This situation is even worsened by the fact that in many cases it cannot be guaranteed that the cooling chain remains unbroken during storage and/or transport.
  • Under these conditions, the risk increases that biopharmaceutics reach the point of care in a state of advanced degradation, and can thus need to be discarded, which involves substantial financial losses, e.g., for the healthcare sponsoring institutions, due to the relatively high market prices for biopharmaceutics, and may, in the worst case, isolate a patient from an essential treatment.
  • It is thus an object of the present invention to provide formulations and methods which help to over come the above mentioned problems.
    • SUMMARY OF THE INVENTION
  • Before the invention is described in detail, it is to be understood that this invention is not limited to the particular component parts of the devices described or process steps of the methods described as such devices and methods may vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an”, and “the” include singular and/or plural referents unless the context clearly dictates otherwise. It is moreover to be understood that, in case parameter ranges are given which are delimited by numeric values, the ranges are deemed to include these limitation values.
  • According to one aspect of the invention, a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5.
  • As used herein, the term “biopharmaceutical protein” relates to physiologically active proteins both isolated from biological resources and/or produced with recombinant means.
  • As used herein, the term “concentration” refers to the weight of a given substance per volume, i.e., to weight concentration. For example, the concentration of a biopharmaceutic is provided in a concentration of mg ml−1.
  • It is important to say that the weight of the biopharmaceutical protein refers to weight of the protein alone, i.e, to the one or more amino acid chain which constitute the protein, plus, if applicable, the one or more glycosylation patterns. In case the protein is provided in a delivery system, or pegylated, or modified elsehow, the weight does not include said modifications, which can add substantial additional weight.
  • As used herein, the term “concentration ratio” refers to the dimensionless ratio of the concentrations of at least two substances. In case, e.g., the biopharmaceutic is provided in a concentration of 10 mg ml−1 and the neutral salt is provided in a concentration of 7.07 mg ml−1, the resulting concentration ratio between the biopharmaceutical protein and the neutral salt would be 10/7.07=1,416.
  • The inventors have for the first time shown in an aqueous formulation comprising a biopharmaceutical aggregations, particularly sub-visible aggregations can be reduced in case said particular concentration ratio between the biopharmaceutic and the neutral salt is provided.
  • Preferably, said concentration ratio is 0.7; 0.8; 0.9; 1.0; 1.1; 1,.2; 1.3; 1.4; 1.5; 1.6; 1.7; 1,8; 1.9; 2.0; 2.1; 2.2; 2.3; 2.4; 2.5; 2.6; 2.7; 2.8; 2.9; 3.0; 3.1; 3.32; 3.3; 3.4; 3.5; 3.6; 3.7; 3,8; 3,9; 4; 4.1; 4.2; 4.3; 4.4; 4.5; 4.6; 4.7; 4.8 4.9; or 5.0.
  • According to a preferred embodiment, the biopharmaceutical protein has between ≧150 and ≦220 amino acid residues and/or a molecular weight between ≧15 and ≦26 kDaltons.
  • Preferably; the protein has 150; 151; 152; 153; 154; 155; 156; 157; 158; 159; 160; 1641; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 177; 178; 179; 180; 181; 182; 183; 184; 185; 186; 187; 188; 189; 190; 191; 192; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 209; 210; 211; 212; 213; 214; 215; 216; 217; 218; 219 or 220 amino acid residues; and/or a molecular weight of 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25 or 26 kDaltons.
  • According to another preferred embodiment, the biopharmaceutical protein is human growth hormone (hGH). Human Growth Hormone (hGH) is a protein-based peptide hormone which stimulates growth, cell reproduction and regeneration in humans and other animals. hGH is a single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland. hGH is primarily used to treat children's growth disorders and adult growth hormone deficiency. Prior to its production by recombinant DNA technology, growth hormone was extracted from human pituitary glands (Cadaver growth hormone, also referred to as NPA growth hormone). Today, hGH is primarily produced with recombinant DNA technology (rhGH, also referred to as somatropin). rhGH has, typically, 191 amino acid residues. The amino acid sequence is available in the UniProt Database under accession No. P01241. Another variant is met-GH (“methionyl-growth hormone”), which has the same amino acid sequence as hGH, with an extra N-terminal methionine.
  • In the context of the present invention the term human growth hormone (hGH) encompasses all the above mentioned variants.
  • According to another preferred embodiment, the formulation further comprises at least one agent selected from the group consisting of
      • a buffer
      • a non-ionic surfactant
      • a tonifier, and/or
      • a preservative.
  • Preferably, said buffer is selected from the group consisting of:
      • Phosphate buffer (Na3PO4, NaH2PO4 and/or Na2HPO4)
      • Citrate,
      • Tris,
      • Succinate,
      • Acetate and/or
      • Histidine.
  • According to another preferred embodiment, said non-ionic surfactant is selected from the group consisting of:
      • Poloxamer, preferably Poloxamer 188 or Poloxamer 184
      • Pluronic F-68, and/or
      • Polysorbate, preferably Polysorbate 20 or Polysorbate 80
  • The term “tonifier”, as used herein, relates to an osmotically active substance which can be used to affect the osmolarity of a pharmaceutical formulation. According to another preferred embodiment, said tonifier is selected from the group consisting of:
      • Mannitol
      • Glycine, and/or
      • Sorbitol.
  • According to another preferred embodiment, said preservative is selected from the group consisting of:
      • phenol
      • meta-cresol,
      • methyl paraben,
      • propyl paraben,
      • benzalconium chloride,
      • benzethonium chloride and/or
      • benzyl alcohol.
  • Suitable concentrations for the buffers, non-ionic surfactants, tonifiers, and/or preservatives are for example shown in Table 2.
  • According to another preferred embodiment of the formulation according to the invention, human growth hormone (hGH) is present in a concentration ranging between ≧3 and ≦20 mg ml−1.
  • Preferably, hGH is present in a concentration of 3; 3.33; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19 or 20 mg ml−1.
  • Particularly preferred concentrations for hGH are for example shown in Table 2.
  • According to another preferred embodiment of the formulation according to the invention, said neutral salt is selected from the group consisting of:
      • Sodium Chloride (NaCl)
  • Preferably, said neutral salt is present in a concentration ranging between ≧2 and ≦100 mg ml−1. Preferably, said neutral salt is present in a concentration of 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99 or 100 mg ml−1.
  • Particularly preferred concentrations for the neutral salt are for example shown in Table 2.
  • According to another preferred embodiment of the formulation according to the invention, the pH of said formulation is in a range between ≧5,8 and ≦6.2. Preferably, said pH is 5,8; 5,9; 6; 6,1 or 6,2. Particularly preferred pH values are for example shown in Table 2.
  • The formulation according to the invention has an optimized stability. Said optimized stability results, e.g., in reduced formation of visible and subvisible aggregates, reduced formation of precipitates, reduced tendency to develop turbidity, particularly after long storage or storage under suboptimal conditions.
  • This feature is particularly beneficial under conditions where it cannot be guaranteed that the cooling chain remains unbroken, as its can for example be the case in emerging markets and/or developing countries.
  • The formation of aggregates can for example be analyzed with light obscuration Particle Counting, Size exclusion HPLC (SE-HPLC)and/or Dynamic light scattering (DLS).
  • Light obscuration Particle Counting (LOPC) is a method that helps to detect and count particles. The nature of particle counting is based upon either light scattering or light obscuration. A high energy light source is used to illuminate the particle as it passes through the detection chamber. The particle passes through the light source (typically a laser) and if light scattering is used, then the redirected light is detected by a photo detector, while, if light obscuration is used, the loss of light is detected. The amplitude of the light scattered or light blocked.
  • Size exclusion HPLC (SE-HPLC) separates particles on the basis of size. It works by trapping smaller molecules in the pores of gel particles. The larger molecules simply pass by the pores as they are too large to enter the pores. Larger molecules therefore flow through the column quicker than smaller molecules, that is, the smaller the molecule, the longer the retention time. SE-HPLC is often used to provide quantitative analysis of protein aggregates and clips, and thus plays an important role in quality control of biopharmaceuticals.
  • Dynamic light scattering (DLS) is a technique in physics, which can be used to determine the size distribution profile of small particles in suspension or polymers in solution. It can also be used to probe the behavior of complex fluids such as concentrated polymer solutions.
  • When light hits small particles the light scatters in all directions (Rayleigh scattering) so long as the particles are small compared to the wavelength (below 250 nm). If the light source is a laser, and thus is monochromatic and coherent, then one observes a time-dependent fluctuation in the scattering intensity. These fluctuations are due to the fact that the small molecules in solutions are undergoing Brownian motion and so the distance between the scatterers in the solution is constantly changing with time. This scattered light then undergoes either constructive or destructive interference by the surrounding particles and within this intensity fluctuation, information is contained about the time scale of movement of the scatterers. Sample preparation either by filtration or centrifugation is critical to remove dust and artifacts from the solution.
  • It is noteworthy to mention that, while SE HPLC is a standard method for quality control in Biopharmaceutics, DLS and LOPC have a better resolution, i.e., they can detect even sub-visible aggregates which cannot be detected with SE HPLC. The present study is the first that makes use of DLS and LOPC for the screening of different formulations for Biopharmaceutics.
  • Accordingly, in this study it has for the first time been shown that aggregations, particularly sub-visible aggregations (which remained undetected in case SE HPLC was used) can be reduced in case a particular ratio between a biopharmaceutic and a neutral saltis provided.
  • According to another aspect of the invention, a method of increasing the stability of a pharmaceutically acceptable aqueous formulation comprising a biopharmaceutical protein is provided. Said method comprises providing the biopharmaceutical protein and the neutral salt in a final concentration ratio in the range of ≧0.7 and ≦5.
  • According to a preferred embodiment, the biopharmaceutical protein is human growth hormone (hGH).
  • Other preferred embodiments of said method can be derived from the above description related to preferred embodiments of the formulation according to the invention.
  • According to another aspect of the invention, the use of a formulation according to the invention for the treatment of at least one condition selected from the group consisting of
      • Growth Hormone Deficiency
      • small for gestational age (SGA) or intrauterine growth retardation (IUGR)
      • Idiopathic Short Stature
      • AIDS Wasting and Cachexia
      • Short Stature Caused by Turner's Syndrome
      • Short Stature Caused by Prader-Willi Syndrome
      • Growth Problems Caused by Short Bowel Syndrome
      • Improper Growth in Children with Renal Disease
      • Rheumatoid Arthritis
      • Osteoporosis
      • X-Linked Hypophosphatemia Rickets
  • According to another aspect of the invention, a primary packaging comprising the formulation according to the invention is provided. Said primary packaging is preferably a vial, a pre-filled syringe, a carpule, a bottle, or a cartridge.
  • In Table 1, different aqueous formulations from the prior art comprising sodium chloride as a neutral salt and human growth hormone as an example for the biopharmaceutical used in the formulation according to the invention are shown. In all cases, the concentration ratio between the biopharmaceutical protein and the neutral salt is smaller than 0.7.
  • In Table 2, different formulations which have been developed under the gist of the present invention are shown. All of these formulations have a concentration ratio between the biopharmaceutical protein and the neutral salt is smaller than 0.7.
  • Table 3 shows other aqueous formulations from the prior art comprising human growth hormone, but without a neutral salt.
  • TABLE 1
    Formulations from the prior art comprising a neutral salt
    Accretropin ® Nutropin ® WO0103741 (Grandis)
    Component Role (Cangene) (Genentech) I III Form. A Form. B Form. C Form. D Form. E
    Volume
    1 ml 2 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    hGH active 5 mg 10 mg 3.33 mg 3.33 mg 3.33 mg 3.33 mg 3.33 mg 3.33 mg 3.33 mg
    ingredient
    Phosphate buffer 10 mM 10 mM 10 mM 10 mM
    Citrate 10 mM 10 mM 10 mM
    NaH2PO4 1.05 mg 1.05 mg
    Na2HPO4 0.17 mg 0.17 mg
    pH
    6 6 6 5.6 5.6 5.6 6 6
    Poloxamer 188 non ionic 2 mg
    Pluronic F-68 surfactant 0.8 mg 0.8 mg 0.8 mg
    Polysorbate 20 4 mg
    Phenol preservative 3.4 mg 5 mg
    Benzyl Alcohol 9 mg 9 mg 9 mg 9 mg 9 mg 9 mg
    Mannitol tonifier
    Glycine
    NaCl neutral salt 7.5 mg 17.4 mg 5.85 mg 5.85 mg 5.9 mg 5.9 mg 5.9 mg 5.9 mg 5.9 mg
    conc ratio 0.667 0.574 0.569 0.569 0.564 0.564 0.564 0.564 0.564
    hGH/NaCl
  • TABLE 2
    exemplary, non-restricting formulations according to the invention
    Formulations according to the invention
    Component Role per cartridge (1.5 ml) 0831RS156_5 0835RS158_5 0835RS158_6 0835RS158_7 0821RS148_5
    Volume 1.5 ml 1.5 ml 1.5 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    hGH active 5 mg 10 g 15 mg 10 g 10 mg 10 mg 10 mg 10 mg
    ingredient
    Phosphate buffer 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM
    Citrate
    NaH2PO4
    Na2HPO4
    pH 6.1 6.1 6.1 6.12 6.12 6.12 6.12 6.12
    Poloxamer 188 non ionic 3 mg 3 mg 4.5 mg 2 mg 3 mg 3 mg 3 mg 2 mg
    surfactant
    Pluronic F-68
    Polysorbate 20
    Phenol preservative 4.5 mg 4.5 mg 3 mg 3 mg 3 mg 3 mg 3 mg
    Benzyl Alcohol 13.5 mg
    Mannitol tonifier 51.5 mg 22.3 mg
    Glycine 27.75 mg
    NaCl neutral salt 5 mg 7 mg 10.5 mg 7.07 mg 3.5 mg 7.07 mg 14 mg 7.07 mg
    conc. ratio hGH/ 2.86 1.43 1.43 1.416 2.86 1.41 0.71 1.4116
    NaCl
  • TABLE 3
    Formulations from the prior art without a neutral salt
    Protropin WO9403198 (Genentech)
    (Genen- Humatrope Norditropin SimpleXx experimental WO0103741 (Grandis)
    Component Role tech) (Eli Lilly) (Novo Nordisk) example reference II IV V VI
    Volume per vial per vial 1.5 ml 1.5 ml 1.5 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    hGH active 5 mg 5 mg 10 mg 15 mg 5.0 mg 5.0 mg 3.33 mg 3.33 mg 3.33 mg 3.33 mg
    ingredient
    Phosphate 1.7 mg
    buffer
    NaH2PO4 0.1 mg 1.05 mg 1.05 mg 1.05 mg 0.85 mg
    Na2HPO4 1.6 mg 1.13 mg 0.17 mg 0.17 mg 0.17 mg 0.31 mg
    Histidine
    1 mg 1 mg 1.7 mg
    pH 7.8 7.5 6 6 6 6 6.2
    Poloxamer non ionic 4.5 mg 4.5 mg 4.5 mg
    188 surfactant
    Pluronic F- 2 mg 2 mg
    68
    Polysorbate 2 mg
    20
    Phenol preservative 4.5 mg 4.5 mg 4.5 mg 2.5 mg
    Benzyl 9 mg 9 mg 9 mg 9 mg
    Alcohol
    Mannitol tonifier 40 mg 25 mg 60 mg 60 mg 58 mg 45 mg 35 mg 35 mg
    Glycine 5 mg 1.7 mg
    NaCl neutral sal
    • BRIEF DESCRIPTION OF THE EXAMPLES AND DRAWINGS
  • Additional details, features, characteristics and advantages of the object of the invention are disclosed in the subclaims, and the following description of the respective FIGS. and examples, which, in an exemplary fashion, show preferred embodiments of the present invention. However, these drawings should by no means be understood as to limit the scope of the invention.
    • EXAMPLE 1 Tonifier Screening
  • Six formulation development batches (No tonifier, Glycine, Mannitol, Sorbitol, and NaCl) were compared. Batches comprising 15 mg hGH in aqueous solution (10.0 mg/ml, solution for injection 1.5 ml cartridge) were stored for 18 months at 5° C.±3° C. (“intended storage condition”), 3 months at 25° C.±2° C./60% relative humidity (“accelerated storage condition”) and 2 weeks at 40° C.±2° C. (“stressed storage condition”). The different formulations are shown in table 4
  • TABLE 4
    Formulation No
    0821RS148_1 0821RS148_2 0821RS148_3 0821RS148_4 0821RS148_5 0821RS148_6
    hGH 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml
    Phosphate 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM
    Glycine 18.17 mg/ml
    Mannitol 44.09 mg/ml 44.09
    Sorbitol 44.09 mg/ml
    NaCl 7.07 mg/ml
    Poloxamer 188 2 mg/ml 2 mg/ml 2 mg/ml 2 mg/ml 2 mg/ml 3 mg/ml
    Phenol 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml
    pH 6.12 6.12 6.12 6.12 6.12 6.12
    water ad 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    tonicity 300 300 300 300 300
  • All tested batches appeared as a clear and colorless solution at the initial time point. During storage at 25° C. all formulations except #0821RS 148-5 (see table 4) containing NaCl turned turbid or opalescent. After 2 months of storage at 5° C.±3° C. formulations containing Mannitol and Sorbitol turned progressively turbid/opalescent while formulation #082IRS148-5 containing NaCl stayed clear over the whole storage period. All observations are backed by particle counting and DLS data. Noteworthy, all aggregation processes could not be monitored by SE-HPLC. At accelerated conditions we observed a marginal increase in aggregation by SE-HPLC. During storage at 25° C. all formulations except #082IRS148-5 containing NaCl turned turbid or opalescent. At stressed conditions we observed a slight increase in aggregation by SE-HPLC. During storage at 40° C. all formulations are clear.
  • Results are shown in FIGS. 1, 2 and 3
    • EXAMPLE 3 Tonifier Screening
  • 6 formulation development batches (no tonifier, Glycine, Mannitol, Sorbitol, NaCl) were compared. Batches comprising 15 mg hGH in aqueous solution (10.0 mg/ml, solution for injection 1.5 ml cartridge) have been stored for 24 months at 5° C.±3° C. (“intended storage condition”), 3 months at 25° C.±2° C./60% relative humidity (“accelerated storage condition”) and 2 weeks at 40° C.±2° C. (“stressed storage condition”). The different formulations are shown in table 5
  • TABLE 5
    Formulation No
    0831RS156_1 0831RS156_2 0831RS156_3 0831RS156_4 0831RS156_5 0831RS156_6
    hGH 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml
    Phosphat 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM
    Glycin 18.17 mg/ml
    Mannitol 44.09 mg/ml 44.09
    Sorbit 44.09 mg/ml
    NaCl 7.07 mg/ml
    Poloxamer 188 2 mg/ml 2 mg/ml 2 mg/ml 2 mg/ml 2 mg/ml 3 mg/ml
    Phenol 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml
    pH 6.12 6.12 6.12 6.12 6.12 6.12
    water ad 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    tonicity 300 300 300 300 300
  • All tested batches appeared as a clear and colorless solution at the initial time point. During storage at 25° C. all formulations except #0831RS156-5 (table 5) containing NaCl turned turbid or opalescent. After ⅔ months of storage at 5° C.±3° C. formulations containing Mannitol and Sorbitol turned progressively turbid/opalescent while formulation #0831RS156-5 containing NaCl stayed clear over the whole storage period. All these observations are furthermore backed by particle counting and DLS data. Noteworthy, all these aggregation processes could not be monitored by SE-HPLC.
  • At accelerated conditions we observed a marginal increase in aggregation by SE-HPLC. During storage at 25° C. all formulations except #083IRS156-5 containing NaCl turned turbid or opalescent. At stressed conditions we observed a slight increase in aggregation by SE-HPLC. During storage at 40° C. all formulations are clear. Results are shown in FIGS. 4, 5 and 6.
    • EXAMPLE 2 Optimization of Neutral Salt Concentration
  • 8 formulation development batches (His/Mannitol, His/Phosphate/Mannitol, Arginine/ Phosphate/Mannitol, Phosphate/Mannitol/0.41 mg/ml NaCl; Phosphate/Mannitol/3.5 mg/ml NaCl, Phosphate/7.07 mg/ml NaCl, Phosphate/Mannitol/14 mg/ml NaCl and Phosphate/0.41 mg/ml NaCl) were compared. Batches comprising 15 mg hGH in aqueous solution (10.0 mg/ml, solution for injection 1.5 ml cartridge) have been stored for 24 months at 5° C.±3° C. (“intended storage condition”) and 3 months at 25° C.±2° C./60% relative humidity (“accelerated condition”). The different formulations are shown in table 6.
  • TABLE 6
    Formulation No
    835RS158_1 835RS158_2 835RS158_3 835RS158_4 835RS158_5 835RS158_6 835RS158_7 835RS158_8
    hGH 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml
    Phosphat 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM 10 mM
    Histidine 1.13 1.13 mg/ml
    Arginine 1.03 mg/ml
    Mannitol 38.7 38.7 mg/ml 38.7 mg/ml 42.85 mg/ml 22.3 mg/ml
    NaCl 0.41 mg/ml 3.5 mg/ml 7.07 mg/ml 41 mg/ml 0.41 mg/ml
    Poloxamer 188 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml
    Phenol 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml 3 mg/ml
    pH 6.12 6.12 6.12 6.12 6.12 6.12 6.12 6.12
    water ad 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
    tonicity 252 277 277 300 300 300 542 54.8
  • All tested batches appeared as a clear and colorless solution at the initial time point. During storage at 25° C. all formulations except #0835RS158-5, 6 and 7 containing 3.5 mg/ml, 7.07 mg/ml and 14 mg/ml NaCl turned turbid or opalescent.
  • After storage at 5° C.±3° C. formulations #0835RS158-5, 6 and 7 stayed clear while all other formulations turned progressively turbid/opalescent. All these observations are furthermore backed by particle counting and DLS data. Noteworthy, all these aggregation processes could not be monitored by SE-HPLC.
  • At accelerated conditions we observed a marginal increase in aggregation by SE-HPLC. During storage at 25° C. all formulations except #0835RS158-5, 6 and 7 turned turbid or opalescent. Results are shown in FIGS. 7 and 8
  • Figures
  • FIG. 1: Particle distribution of samples stored at 5° C. in the first tonifier screening experiment (example 1, “intended storage condition”), as determined with light obscuration Particle Counting. In general, sub-visible particle levels were high at the initial time point and shows elevated levels for formulations containing no tonifier, Glycine, Mannitol and Sorbitol. NaCl containing formulations showed the lowest sub-visible particle levels. These findings are further backed by DLS data and appearance data.
  • FIG. 2: Particle distribution of samples stored at 25° C. in the first tonifier screening experiment (example 1, “accelerated storage condition”), as determined with light obscuration Particle Counting. In general, sub-visible particle levels were high at the initial time point but stayed at elevated levels for formulations containing no tonifier, Glycine and Sorbitol. NaCl containing formulations showed the lowest sub-visible particle levels. These findings are further backed by DLS data and appearance data.
  • FIG. 3: Particle distribution of samples stored at 40° C. in the first tonifier screening experiment (example 1, “stressed storage conditions”), as determined with light obscuration Particle Counting. In general, sub-visible particle levels were highest at the initial time point. All formulations stored for 1 week and 2 weeks at 40° C. showed a significant decrease in sub-visible particle levels.
  • FIG. 4: Particle distribution of samples stored at 5° C. in the second tonifier screening experiment (example 3, “intended storage condition”), as determined with light obscuration Particle Counting. In general, sub-visible particles progressively increase for formulations containing no tonifier and Glycine and pronounced for formulations containing Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels. These findings are further backed by DLS data and appearance data.
  • FIG. 5: Particle distribution of samples stored at 25° C. in the second tonifier screening experiment (example 3, “accelerated storage condition”), as determined with light obscuration Particle Counting. In general, sub-visible particles stayed at elevated levels for formulations containing no tonifier, Glycine, Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels. These findings are further backed by DLS data and appearance data.
  • FIG. 6: Particle distribution of samples stored at 40° C. in the second tonifier screening experiment (example 3, “stressed storage condition”), as determined with light obscuration Particle Counting. In general, sub-visible particle levels were highest at the end of storage after 2 weeks at 40° C. Sub-visible particles were at elevated levels for formulations containing no tonifier, Glycine, Sorbitol and Mannitol. NaCl containing formulations showed the lowest sub-visible particle levels. These findings are further backed by DLS data and appearance data.
  • FIG. 7: Particle distribution of samples stored at 5° C. in the optimization of neutral salt concentration experiment (example 2, “intended storage condition”), as determined with light obscuration Particle Counting. Sub-visible particle levels were elevated for all batches except for formulations containing 3.5 mg/ml, 7.07 mg/ml and 14 mg/ml NaCl during storage at 5° C. This finding is further backed by DLS data (data not shown).
  • FIG. 8: Particle distribution of samples stored at 25° C. in the optimization of neutral salt concentration experiment (example 2, “accelerated condition”), as determined with light obscuration Particle Counting. Sub-visible particle levels were elevated for all batches except for formulations containing 3.5 mg/ml, 7.07 mg/ml and 14 mg/ml NaCl during storage at 25° C. This finding is further backed by DLS data (data not shown).
  • Methods
  • Experimental methods are shown in the following tables and lists:
  • Storage Conditions Location
    5° C. ± 3° C. Cold room B101/124 - intended storage
    25° C. ± 2° C./60% ± 5% Climate chamber B101/BPO/AL3 -
    relative humidity accelerated storage
    40° C. ± 2° C. Incubator B101/BPO/AL3 - stressed storage
  • Test Analytical Method
    Appearance content and container Visual evaluation
    pH Potentiometric determination
    Identity/Purity nRPC (nanoflow reversed phase
    HPLC)
    Product related impurities and SE HPLC (size exclusion HPLC)
    substances/ Content
    Aggregation I DLS (Dynamic Light scattering)
    Aggregation II light obscuration Particle Counting
    Aggregation III (Only in example 2) Microflow Imaging

Claims (17)

1. A pharmaceutieally acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of ≧0.7 and ≦5.
2. The formulation according to claim 1, wherein the biopharmaceutical protein has between ≧150 and ≦220 amino acid residues and/or a molecular weight between ≧15 and ≦26 kDaltons.
3. The formulation according to claim 1, wherein the biopharmaceutical protein is human growth hormone (hGH).
4. The formulation according to claim 1, wherein said formulation further comprises at least one agent selected from the group consisting of
a buffer,
a non-ionic surfactant,
a tonifier, and/or
a preservative.
5. The formulation according to claim 4, wherein said buffer is selected from the group consisting of:
Phosphate buffer (Na3PO4, NaH2PO4 and/or Na2HPO4),
Citrate,
Tris,
Succinate,
Acetate, and/or
Histidine.
6. The formulation according to claim 4, wherein said non-ionic surfactant is selected from the group consisting of:
Poloxamer, preferably Poloxamer 188 or Poloxamer 184,
Pluronic F-68, and/or
Polysorbate, preferably Polysorbate 20 or Polysorbate 80.
7. The formulation according to claim 4, wherein said tonifier is selected from the group consisting of:
Mannitol,
Glycine, and/or
Sorbitol.
8. The formulation according to claim 4, wherein said preservative is selected from the group consisting of:
Phenol,
meta-cresol,
methyl paraben,
propyl paraben,
benzalconium chloride,
benzethonium chloride, and/or
Benzyl Alcohol.
9. The formulation according to claim 3, wherein human growth hormone (hGH) is present in a concentration ranging between ≧3 and ≦20 mg ml−1.
10. The formulation according to claim 1, wherein said neutral salt is
Sodium Chloride (NaCl).
11. The formulation according to claim 1, wherein said neutral salt is present in a concentration ranging between ≧2 and ≦100 mg ml−1.
12. The formulation according to claim 1, wherein the pH of said formulation is in a range between ≧5.8 and ≦6.2
13. The formulation according to claim 1, wherein said formulation has an optimized stability.
14. A method of increasing the stability of a pharmaceutically acceptable aqueous formulation comprising a biopharmaceutical protein, which method comprises providing the biopharmaceutical protein and the neutral salt in a final concentration ration in the range of ≧0.7 and ≦5.
15. The method of claim 14, wherein the biopharmaceutical protein is human growth hormone (hGH).
16. Use of a formulation according to claim 14, for the treatment of at least one condition selected from the group consisting of
Growth Hormone Deficiency,
small for gestational age (SGA) or intrauterine growth retardation (IUGR),
Idiopathic Short Stature,
AIDS Wasting and Cachexia,
Short Stature Caused by Turner's Syndrome,
Short Stature Caused by Prader-Willi Syndrome,
Growth Problems Caused by Short Bowel Syndrome,
Improper Growth in Children with Renal Disease,
Rheumatoid Arthritis,
Osteoporosis, and
X-Linked Hypophosphatemic Rickets.
17. A primary packaging comprising the formulation according to claim 1.
US14/234,652 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein Abandoned US20140194356A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/234,652 US20140194356A1 (en) 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161511168P 2011-07-25 2011-07-25
US14/234,652 US20140194356A1 (en) 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
PCT/EP2012/064613 WO2013014196A1 (en) 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/064613 A-371-Of-International WO2013014196A1 (en) 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/913,550 Continuation US11446381B2 (en) 2011-07-25 2018-03-06 Stable aqueous formulation for growth hormone

Publications (1)

Publication Number Publication Date
US20140194356A1 true US20140194356A1 (en) 2014-07-10

Family

ID=46634124

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/234,652 Abandoned US20140194356A1 (en) 2011-07-25 2012-07-25 Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US15/913,550 Active 2033-03-08 US11446381B2 (en) 2011-07-25 2018-03-06 Stable aqueous formulation for growth hormone

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/913,550 Active 2033-03-08 US11446381B2 (en) 2011-07-25 2018-03-06 Stable aqueous formulation for growth hormone

Country Status (5)

Country Link
US (2) US20140194356A1 (en)
EP (1) EP2736490A1 (en)
JP (1) JP6363949B2 (en)
BR (1) BR112014001921B1 (en)
WO (1) WO2013014196A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112494638A (en) * 2020-12-22 2021-03-16 深圳科兴药业有限公司 Human growth hormone injection composition and preparation method thereof
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448225B2 (en) * 1988-04-15 2002-09-10 Genentech, Inc. Human growth hormone aqueous formulation
US6593296B1 (en) * 1996-02-12 2003-07-15 Csl Limited Stabilized growth hormone formulation and method of preparation thereof
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ255158A (en) * 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
JP3723857B2 (en) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 Aqueous pharmaceutical composition containing human growth hormone
ATE386501T1 (en) 1999-07-12 2008-03-15 Sandoz Ag FORMULATIONS OF GROWTH HORMONES
MXPA05000413A (en) * 2002-07-09 2005-07-22 Sandoz Ag LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL.
JP4949828B2 (en) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム Stabilization of growth hormone in solution
BRPI0418115A (en) * 2003-12-23 2007-04-17 Pharmacia Corp stable liquid growth hormone formulation
WO2005105148A2 (en) * 2004-04-07 2005-11-10 Ares Trading S.A.- Liquid growth hormone formulation
CA2780554C (en) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448225B2 (en) * 1988-04-15 2002-09-10 Genentech, Inc. Human growth hormone aqueous formulation
US6593296B1 (en) * 1996-02-12 2003-07-15 Csl Limited Stabilized growth hormone formulation and method of preparation thereof
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chi et al. Pharmaceut. Res. 20(9): 1325-1336, 2003. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
CN112494638A (en) * 2020-12-22 2021-03-16 深圳科兴药业有限公司 Human growth hormone injection composition and preparation method thereof

Also Published As

Publication number Publication date
BR112014001921B1 (en) 2022-05-10
BR112014001921A2 (en) 2019-04-02
EP2736490A1 (en) 2014-06-04
WO2013014196A1 (en) 2013-01-31
US20180256722A1 (en) 2018-09-13
US11446381B2 (en) 2022-09-20
JP6363949B2 (en) 2018-07-25
JP2014528919A (en) 2014-10-30

Similar Documents

Publication Publication Date Title
US11123406B2 (en) Rapid-acting insulin compositions
Jain et al. A review on parenteral delivery of peptides and proteins
KR100987311B1 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
CN107920992B (en) Quick-acting insulin composition
US9844594B2 (en) Liquid formulations for an anti-TNF α antibody
EP3532029B1 (en) Liquid pharmaceutical composition
RU2558821C2 (en) DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+
BRPI0818324B1 (en) liquid formulation containing luteinizing hormone (lh) or a variant thereof, its use, presentation, process for its preparation and pharmaceutical composition
EA029193B1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
TW201605489A (en) Stable formulation of INSULIN GLULISINE
US20190284282A1 (en) Stable pharmaceutical composition
US11446381B2 (en) Stable aqueous formulation for growth hormone
CN111375057B (en) Pharmaceutical formulation comprising anti-Her 2 monoclonal antibody
US20160015789A1 (en) FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN
US10695395B2 (en) Collagen 7 compositions and methods of using the same
US20240239900A1 (en) A method of improving stability of an antibody formulation
US20210347877A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
US20210315978A1 (en) Formulations for improved stability of recombinant human parathyroid hormone
TW201925231A (en) Pharmaceutical composition comprising anti-human alpha9 integrin antibody
EP4438035A1 (en) High concentration administration formulation of hgh fusion protein
EP3335729A1 (en) Etanercept composition having improved stability

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANDOZ AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRAGL, BERNT;FUERTINGER, SABINE;SIGNING DATES FROM 20140210 TO 20140217;REEL/FRAME:032348/0069

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION